Related Experiment Video

Updated: Sep 6, 2025

High-speed Video Microscopy Analysis for First-line Diagnosis of Primary Ciliary Dyskinesia
05:32

High-speed Video Microscopy Analysis for First-line Diagnosis of Primary Ciliary Dyskinesia

Published on: January 19, 2022

4.5K

Long-Term Azithromycin Treatment in Pediatric Primary Ciliary Dyskinesia: A Retrospective Study

Yuhong Guan1, Xiang Zhang1, Haiming Yang1

  • 1Department of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.

Frontiers in Pediatrics
|June 27, 2022
PubMed

Insights

Long-term azithromycin (AZM) treatment reduced respiratory infections and stabilized lung disease in pediatric primary ciliary dyskinesia (PCD) patients. AZM treatment showed potential benefits for PCD patients with compromised lung function.

Area of Science:

  • Medical Research
  • Genetics
  • Pulmonology

Background:

  • Primary ciliary dyskinesia (PCD) is a rare genetic disorder primarily affecting lung function.
  • Limited data exists on the long-term outcomes of azithromycin (AZM) treatment in pediatric PCD patients.

Purpose of the Study:

  • To evaluate the effects of AZM treatment on the disease progression of pediatric patients diagnosed with PCD.
  • To compare clinical outcomes, pulmonary function, and CT findings between AZM-treated and untreated PCD patients.

Main Methods:

  • Retrospective follow-up study of PCD patients diagnosed between 2009 and 2021.
  • Comparison of clinical outcomes, pulmonary function tests (FEV1%, FVC%), and chest CT findings.
  • Analysis of respiratory exacerbations and exercise intolerance between AZM-treated (n=34) and untreated (n=37) groups.

Main Results:

  • AZM-treated patients experienced significantly fewer respiratory exacerbations annually (1.4 vs. 3.0, P=0.001) and less exercise intolerance.
  • While FEV1% and FVC% predicted values showed a greater increase from baseline in the AZM-treated group, the difference was not statistically significant.
  • No significant baseline differences were observed between groups, except for lower FEF25-75% predicted in the AZM-treated group.

Conclusions:

  • Long-term azithromycin treatment appears to reduce respiratory infection frequency in pediatric PCD patients.
  • AZM treatment may help stabilize pulmonary disease progression, particularly in children with pre-existing poorer lung function.
  • Further research is warranted to fully elucidate the long-term benefits and mechanisms of AZM in PCD management.
Abstract

Keywords:
azithromycinlung functionpediatricprimary ciliary dyskinesiatreatment

More Related Videos

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

5.0K
Collection, Expansion, and Differentiation of Primary Human Nasal Epithelial Cell Models for Quantification of Cilia Beat Frequency11:13

Collection, Expansion, and Differentiation of Primary Human Nasal Epithelial Cell Models for Quantification of Cilia Beat Frequency

Published on: November 10, 2021

4.2K

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
220
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
235
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
442
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
292
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K